The Center for Advanced Genetic Screening.
Cellecta is a contract research company whose primary focus is to develop advanced high-throughput (HT) genetic screen technologies and their applications for the discovery and functional characterization of novel therapeutic targets and drugs.
With more than 6 years of HT genetic screening experience, Cellecta is at the forefront of the HT genetic screening revolution.
> Learn more about our products and services
> Learn more about Cellecta
High-Throughput Screening for Bioactive Peptides
Cellecta introduces a novel proprietary technological platform for cost-effective HTS of 50K-500K rationally designed peptides for biological activity in a wide range of disease-relevant cell models. Search the new “druggable” space to develop next-generation biologics with unique mechanisms of action against cell surface receptors.
High-Throughput RNAi Screening with Pooled shRNA Libraries
Next generation, cost-effective RNAi screens with pooled lentiviral shRNA libraries. Choose any or all steps, from library construction to screening to data analysis.
Stable Reporter and Overexpression Cell Line Development
Using lentiviral technology, we can generate customized transcriptional reporter, overexpression, and knockdown stable cell lines using GFP, RFP, PuroR, or other marker.
Brochure
View our company brochure for an overview of Cellecta's RNAi Screening and related services.> Download Now
Upcoming Events
June 23, 2009
Cellecta research scientist Debbie Deng will be a guest speaker at the 2009 World Cancer Congress held in Beijing, China. The topic will be "New Technologies for RNAi Screening with Pooled Lentiviral shRNA Libraries" and will be presented at 14:30 in Track 3-5, Rational Drug Design vs. High Throughput Cancer Drug Screening.